UBS

A senior syndicate member of UBS's Asia debt capital markets team has left the firm.

Insurance claims processor Solera Holdings has just three more days of roadshowing to persuade investors to get involved in its $4bn bond and leveraged loan financing, with the jury out on whether a strong week of meetings in the US can trump the torrid time the company had when courting investors in Europe, write Max Bower and Victor Jimenez.

Helaba brought the biggest Pfandbrief since 2011 on Tuesday, pulling in €1.25bn with a long four year deal. It was the first ever euro benchmark covered bond issued with a zero percent coupon, but given the persistent low interest rate environment it is unlikely to be the last, with some bankers alarmed at the prospect of negative yielding covered bonds.

Hoffmann La-Roche returned to the European corporate bond market exactly a year after its last offering in euros and as it did then, achieved aggressive pricing for a €650m bond.

Indonesia-based power producer Cikarang Listrindo is planning to launch the country's largest IPO for almost a year.

As Solera Holdings began on Tuesday in New York the last leg of its $2bn bond roadshow, investors in the US voiced their surprise at how negative some of its European counterparts remain about the success of the deal.

The covered bond market could see the second Singaporean deal soon, with United Overseas Bank (UOB) mandating leads for a series of European investor meetings that could result in its first deal.

Mexico is looking to sell its fifth euro denominated bond in four years after releasing initial price thoughts for six and 15 year tranches on Tuesday.

Indonesia is gearing up for its largest IPO in almost a year, with power producer Cikarang Listrindo eyeing a $300m listing on the Jakarta Stock Exchange in the first half of 2016.

UBS has hired a new head of emerging market sales.

After LeasePlan postponed its €1.55bn bond last week, US software producer Solera Holdings stands alone in the European high yield market as it roadshows a $2bn acquisition bond. But some bankers said that it will be hard for the Texan issuer to draw any lessons from LeasePlan's pain.

Amgen, the US multinational bio-pharmaceutical company, on Monday announced plans for its debut bond in Swiss francs, a transaction that bankers hope could turn a gloomy February market around.